Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMP vs R-CHOP in untreated mantle cell lymphoma ineligible for transplant
CTR20131927Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Started Jun 2016; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20131927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131927.